RxDoctor Payments Data

Michael Cutler, DO

Clinical Cardiac Electrophysiology · Murray, UTNPI 1417025628

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Biosense Webster, Inc. at 40.2% of the total. Reporting peaked in 2023 at $24,774 and has fallen 67.9% since, to $7,954 in 2025.

$69,554in general payments, 2019–2025

Across 162 payments — averaging $429.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biosense Webster, Inc.$28K
  • Boston Scientific$20K
  • Janssen Scientific Affairs, LLC$7K
  • Atricure, Inc.$5K
  • Medtronic$3K
  • Altathera Pharmaceuticals LLC$2K
  • plus $5K from 6 others
$256,614in research payments, 2019–2025

Across 57 payments — averaging $4501.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$128K
  • Medical Device Business Services, Inc.$48K
  • Biosense Webster, Inc.$39K
  • Atricure, Inc.$38K
  • Novartis$3K

What the payments were for

  • Consulting fees$39,18556%
  • Speaking & faculty fees$1,0001%
  • Travel & lodging$22,60933%
  • Food & beverage$6,75910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$69,554 in reported general payments places this provider in the 75th percentile of 29 clinical cardiac electrophysiology providers in Utah.

See all clinical cardiac electrophysiology providers in Utah

Medicare billing

Part B allowed, 2024
$184,859
Medicare patients
1,016
Services billed
2,703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban529$619,894
XareltoRivaroxaban98$117,840
MultaqDronedarone Hcl22$25,512
Flecainide Acetate405$16,248
Dabigatran EtexilateDabigatran Etexilate Mesylate26$7,380
Metoprolol Succinate285$4,040
Dofetilide28$3,414
Diltiazem 24hr Er (Cd)Diltiazem Hcl85$2,266
Ranolazine ErRanolazine22$1,898
Amiodarone Hcl80$1,349
Mexiletine Hcl12$1,214
SotalolSotalol Hcl27$433
Pantoprazole Sodium51$338
Metoprolol Tartrate25$314
Colchicine16$249

Paid to pharmacies, not to this prescriber.

Other clinical cardiac electrophysiology in Murray

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →